Clinical trial NCT04395612 - References

Cervical Cancer — Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer

Citation(s)

•   Chen WQ, Li H, Sun KX, Zheng RS, Zhang SW, Zeng HM, Zou XN, Gu XY, He J
  [Report of Cancer Incidence and Mortality in China, 2014]. Zhonghua Zhong Liu Za Zhi. 2018 Jan 23;40(1):5-13. doi: 10.3760/cma.j.issn.0253-3766.2018.01.002. Chinese.
•   Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, Zhao CH, Lin L, Brunetti AE, Fu YL, Wang J, Paradiso A, Xu JM
  Expression and prognostic value of VEGFR-2, PDGFR-ß, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2013 Apr 3;32:
•   Eskander RN, Tewari KS
  Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. Clin Ther. 2015 Jan 1;37(1):20-38. doi: 10.1016/j.clinthera.2014.11.010. Review.
•   Fakhrejahani E, Toi M
  Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. Jpn J Clin Oncol. 2014 Mar;44(3):197-207. doi: 10.1093/jjco/hyt201. Epub 2014 Jan 27. Review.
•   Kaelin WG Jr
  The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005 Sep;5(9):689-98. Review.
•   Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A
  Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist. 2014 Nov;19(11):1156-68. doi: 10.1634/theoncologist.2014-0032.
•   Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators
  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164. Epub 2016 Oct 7.
•   Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A
  Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.

A Clinical Proof-of-concept Study Evaluating Efficacy and Safety of ZL-2306 (Niraparib) Combined With Brivanib or Toripalimab in Patients With Metastatic, Recurrent, and Persistent Cervical Cancer

Details for clinical trial NCT04395612